ABIOMED, Inc.  

(Public, NASDAQ:ABMD)   Watch this stock  
Find more results for ABMD
270.26
+2.52 (0.94%)
Real-time:   10:42AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 264.45 - 271.91
52 week 112.20 - 271.91
Open 267.90
Vol / Avg. 103,971.00/435,154.00
Mkt cap 11.95B
P/E 109.83
Div/yield     -
EPS 2.46
Shares 44.28M
Beta 0.36
Inst. own 90%
May 2, 2018
Q4 2018 Abiomed Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Feb 15, 2018
Abiomed Inc at Leerink Partners Global Healthcare Conference
Feb 1, 2018
Q3 2018 Abiomed Inc Earnings Release
Feb 1, 2018
Q3 2018 Abiomed Inc Earnings Call - Webcast
Jan 8, 2018
Abiomed Inc at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin 23.01% 11.70%
Operating margin 29.06% 20.24%
EBITD margin - 21.63%
Return on average assets 20.11% 10.70%
Return on average equity 22.98% 12.70%
Employees 908 -
CDP Score - -

Address

22 CHERRY HILL DR
DANVERS, MA 01923-2575
United States - Map
+1-978-7775410 (Phone)
+1-978-7778411 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Officers and directors

Michael R. Minogue Chairman of the Board, President, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ian McLeod Principal Financial Officer, Principal Accounting Officer, Vice President, Controller
Bio & Compensation  - Reuters
David M. Weber Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
William J. Bolt Senior Vice President, Global Quality, Regulatory and Clinical Operations
Age: 65
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Andrew J. Greenfield Vice President, General Manager - Global Marketing
Age: 44
Bio & Compensation  - Reuters
Michael G. Howley Vice President, General Manager - Global Sales and Marketing
Age: 53
Bio & Compensation  - Reuters
Dorothy E. Puhy Lead Independent Director
Age: 66
Bio & Compensation  - Reuters
Jeannine M. Rivet Independent Director
Age: 69
Bio & Compensation  - Reuters
Eric A. Rose M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Martin P. Sutter Independent Director
Age: 62
Bio & Compensation  - Reuters